Stephens Reaffirms Overweight Rating for Kymera Therapeutics (NASDAQ:KYMR)

Kymera Therapeutics (NASDAQ:KYMR)‘s stock had its “overweight” rating reissued by stock analysts at Stephens in a research report issued on Tuesday,Benzinga reports. They currently have a $60.00 price objective on the stock. Stephens’ price target indicates a potential upside of 37.39% from the stock’s current price.

A number of other equities analysts also recently commented on the company. Morgan Stanley lifted their price target on Kymera Therapeutics from $45.00 to $49.00 and gave the stock an “equal weight” rating in a research note on Wednesday, November 6th. BMO Capital Markets began coverage on Kymera Therapeutics in a research report on Friday, December 6th. They issued a “market perform” rating and a $55.00 target price for the company. Truist Financial reissued a “buy” rating and set a $53.00 price target (down from $54.00) on shares of Kymera Therapeutics in a research report on Friday, November 1st. Wells Fargo & Company raised shares of Kymera Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their price objective for the stock from $38.00 to $57.00 in a report on Monday, December 2nd. Finally, Guggenheim increased their target price on shares of Kymera Therapeutics from $45.00 to $52.00 and gave the stock a “buy” rating in a report on Friday, November 1st. Three investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Kymera Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $55.06.

Kymera Therapeutics Trading Up 7.5 %

Shares of KYMR traded up $3.06 during midday trading on Tuesday, reaching $43.67. 123,180 shares of the company were exchanged, compared to its average volume of 515,852. The stock has a 50-day moving average price of $42.83 and a 200-day moving average price of $44.56. Kymera Therapeutics has a 1-year low of $27.47 and a 1-year high of $53.27. The company has a market cap of $2.83 billion, a price-to-earnings ratio of -18.60 and a beta of 2.19.

Kymera Therapeutics (NASDAQ:KYMR) last issued its quarterly earnings results on Thursday, October 31st. The company reported ($0.82) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.01. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. The business had revenue of $3.74 million during the quarter, compared to analyst estimates of $10.34 million. During the same quarter in the previous year, the firm earned ($0.90) earnings per share. The business’s revenue was down 20.9% compared to the same quarter last year. Equities research analysts anticipate that Kymera Therapeutics will post -2.79 earnings per share for the current year.

Insider Buying and Selling at Kymera Therapeutics

In other Kymera Therapeutics news, insider Ellen Chiniara sold 3,129 shares of the firm’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $41.75, for a total value of $130,635.75. Following the completion of the transaction, the insider now directly owns 54,826 shares in the company, valued at $2,288,985.50. This trade represents a 5.40 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. 15.82% of the stock is owned by corporate insiders.

Institutional Trading of Kymera Therapeutics

Several institutional investors have recently made changes to their positions in the stock. Mirae Asset Global Investments Co. Ltd. lifted its position in Kymera Therapeutics by 27.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,336 shares of the company’s stock worth $114,000 after buying an additional 504 shares in the last quarter. Harbor Capital Advisors Inc. raised its holdings in shares of Kymera Therapeutics by 1.7% during the fourth quarter. Harbor Capital Advisors Inc. now owns 40,987 shares of the company’s stock worth $1,649,000 after acquiring an additional 684 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Kymera Therapeutics by 8.8% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,289 shares of the company’s stock valued at $534,000 after purchasing an additional 915 shares during the last quarter. Values First Advisors Inc. acquired a new stake in Kymera Therapeutics during the third quarter valued at $61,000. Finally, Handelsbanken Fonder AB grew its stake in shares of Kymera Therapeutics by 12.3% in the 3rd quarter. Handelsbanken Fonder AB now owns 17,300 shares of the company’s stock valued at $819,000 after buying an additional 1,900 shares in the last quarter.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.